MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hep.0000000000001720

Медицинская библиотека · Hepatology (Baltimore, Md.) · 2026

Real-world impact of AUD pharmacotherapy on healthcare utilization, cost, and cost-effectiveness in the United States.

Nguyen Chi M, Blaney Hanna L, Su Jing, Jiang Shihui, Li Yang, Li Yining, Gawrieh Samer, Tu Wanzhu, Liangpunsakul Suthat

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Alcohol use disorder (AUD) imposes a substantial burden on healthcare systems in the United States. Although pharmacological treatments are effective, they remain underutilized. Real-world evidence on the economic impact and clinical effectiveness of AUD pharmacotherapy is limited.

APPROACH AND

RESULTS

We conducted a retrospective cohort study using Optum's de-identified Clinformatics Data Mart Database, including individuals aged ≥21 years with a new diagnosis of AUD between 2017 and 2023. Patients who initiated AUD pharmacotherapy within 1 year of diagnosis (treated group) were matched 1:1 to untreated counterparts using propensity score matching. Outcomes included alcohol-associated emergency department (ED) visits, inpatient (IP) admissions, and associated medical charges during a 1-year follow-up. Cost-effectiveness was assessed using incremental cost-effectiveness ratios (ICERs). Among 218,260 patients with AUD (109,130 matched pairs), MAUD use was associated with a significantly lower likelihood of alcohol-associated hospitalization (37.6% vs. 41.4%, p <0.001) and lower total alcohol-associated medical charges ($47,697 vs. $50,403, p <0.001), with savings driven predominantly by reduced IP utilization. Cost savings were observed across all liver disease strata and were greatest in patients with moderate-to-severe liver disease, where MAUD was associated with nearly $27,000 lower mean IP charges and a 9% absolute reduction in hospitalization risk. The greatest efficiency was also observed in patients with moderate-to-severe liver disease: each $0.03 spent on AUD medication corresponded to $1 in medical cost savings.

CONCLUSIONS

AUD pharmacotherapy is significantly associated with lower alcohol-associated healthcare utilization, particularly IP care, and medical charges in real-world settings, with the largest economic benefits observed in patients without advanced liver disease. These findings support broader implementation of pharmacologic treatment for AUD, including in patients with ALD, and underscore the importance of early intervention to maximize cost-effectiveness.

Для цитирования: Nguyen Chi M, Blaney Hanna L, Su Jing, Jiang Shihui, Li Yang, Li Yining, Gawrieh Samer, Tu Wanzhu, Liangpunsakul Suthat. Real-world impact of AUD pharmacotherapy on healthcare utilization, cost, and cost-effectiveness in the United States.. Hepatology (Baltimore, Md.). 2026. DOI: 10.1097/hep.0000000000001720.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.